UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.

“We are proud that the AUA selected the ATLAS post-hoc analysis as a podium presentation,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “The results highlight UGN-102’s potential to help significantly advance treatment for patients with newly diagnosed and recurrent LG-IR-NMIBC, a highly prevalent and recurrent disease. Additionally, we are excited to see additional independent real-world evidence related to JELMYTO treatment of LG-UTUC patients in a diverse patient types.”

Key details of UGN-102 and JELMYTO abstracts accepted by AUA:

Abstract Title	Presentation Details
Response to Primary Chemoablation with UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial	Podium Oral Presentation: Abstract ID 24-6641, Saturday, May 4, 2:20-2:30 PM CDT, Location 304A	Presenter: Dr. William Huang
Longitudinal Follow Up of Multicenter Study of UGN-101 for Upper Tract Urothelial Cancer	Podium Oral Presentation: Abstract ID 24-7470, Sunday, May 5, 11:10-11:20 AM CDT, Location 301A	Presenter: Dr. Yair Lotan
Exploring Recurrence After Initial Response to UGN-101 Induction in Expanded Settings	Podium Oral Presentation: Abstract ID 24-7534, Sunday May 5, 11:20-11:30 AM CDT, Location 301A	Presenter: Dr. Adam Feldman
Mitomycin-containing Reverse Thermal Gel UGN-101 for Upper Tract Urothelial Carcinoma: Retrograde Instillation in Clinic and Outcomes	Video Presentation: Abstract ID 24-7720, Saturday, May 4, 10:50-11:00 AM CDT, Location Video Abstract Theater	Presenter: Dr. Golena Moncaleano